Johnson & Johnson: Steady Growth Play


  • Johnson & Johnson has steadily been growing the business.
  • After having deleveraged its balance sheet, the company announced a $16.6 billion deal for Abiomed.
  • This deal and spin-off of the consumer health business, aimed to isolate liabilities, creates comfort for investors.
  • J&J remains a long-term diverse growth play at a reasonable valuation.

Johnson & Johnson Medical Products company in Markham, Ontario


Shares of Johnson & Johnson (NYSE:JNJ) have continued to do well, with many moving parts taking place at the business. In the summer of 2020, I updated my thesis after a $6 billion “bolt-on” deal for Momenta, adding to its diversified growth engine.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

If you like to see more ideas, please subscribe to the premium service “Value in Corporate Events” here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!

Leave a Reply

Your email address will not be published. Required fields are marked *